Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

Top 5 Contagion® News Articles for the Week of October 22, 2017

OCT 28, 2017 | CONTAGION® EDITORIAL STAFF

#5: Tackling Vaccine-Preventable Diseases: Challenges and Advancements

“Innovation drives progress,” according to the US Food and Drug Administration (FDA). Innovation is desperately needed in order to develop new agents and therapeutic biological products that could help those in need.

There have been many agents that the FDA has proved as safe and effective over the years, but a comprehensive database consisting of that information did not exist—until Michael S. Kinch, PhD, and his colleagues, who, set out to catalog every drug ever approved by the FDA. They ended up producing “the most comprehensive database in existence.” Not even the FDA had such an archive, and thus, its creation sparked dozens of academic papers and even a book.

Read more about the challenges and advancements associated with vaccine-preventable diseases, here.

#4: Darunavir-Based Single Tablet HIV Regimen Achieves Primary Endpoint

Janssen Pharmaceuticals has announced that their phase 3 AMBER study has achieved its primary endpoint, which focused on virologic response rate. The investigational darunavir-based single tablet regimen (STR) has proved to be “non-inferior” to darunavir/cobicistat (D/C) plus emtricitabine and tenofovir disoproxil fumarate (F/TDF) in HIV-1-positive adults without previous treatment.

The safety and efficacy results of the 48-week phase 3 “randomized, double-blind, active-controlled, international, multi-center, non-inferiority study” will be presented this week at the 16th European AIDS Conference, being held in Milan, Italy, according to the press release.

Read more about the darunavir-based regimen, here.

FEATURED
Big advances in treatment can